Key Points
- CEO Robert Blum sold 97,926 Cytokinetics shares for approximately $6.79 million at an average price of $69.33, reducing his direct ownership by 20.26%. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
- Cytokinetics reported a quarterly loss of $1.50 per share, beating analysts’ $1.63 loss estimate, while revenue of $28.62 million exceeded expectations but fell 57.1% year over year.
- Analyst sentiment remains broadly positive: 18 analysts rate the stock a Buy, with an average price target of $103.37, despite some sell ratings and investor concerns about the commercial potential of Myqorzo.
Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) Director Robert Landry sold 1,000 shares of the business's stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $72.13, for a total value of $72,130.00. Following the transaction, the director owned 8,184 shares in the company, valued at $590,311.92. The trade was a 10.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Cytokinetics Trading Down 4.3%
Shares of CYTK stock opened at $69.31 on Wednesday. The stock has a 50 day simple moving average of $77.46 and a 200-day simple moving average of $72.80. The company has a market cap of $8.62 billion, a price-to-earnings ratio of -9.60 and a beta of 0.36. Cytokinetics, Incorporated has a 12-month low of $47.22 and a 12-month high of $88.31.
Cytokinetics (NASDAQ:CYTK - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, beating analysts' consensus estimates of ($1.63) by $0.13. The business had revenue of $28.62 million during the quarter, compared to analysts' expectations of $17.59 million. During the same quarter last year, the firm earned ($1.12) earnings per share. The firm's quarterly revenue was down 57.1% compared to the same quarter last year. On average, equities analysts forecast that Cytokinetics, Incorporated will post -5.98 earnings per share for the current fiscal year.
More Cytokinetics News
Here are the key news stories impacting Cytokinetics this week:
- Neutral Sentiment: CEO Robert I. Blum sold a combined 105,426 shares for approximately $7.34 million across September 14–15, reducing his direct holdings by roughly 22%. Because the sales were made under a pre-arranged Rule 10b5-1 plan, they may reflect scheduled portfolio diversification rather than a reaction to new company-specific information. SEC Form 4 filing
- Neutral Sentiment: Director Robert Landry separately sold 1,000 shares for $72,130 under a 10b5-1 plan. The relatively small transaction adds to the insider-selling activity but is not, by itself, a major fundamental signal. SEC director Form 4 filing
- Neutral Sentiment: Cytokinetics announced its ninth annual communications grant program, which will support cardiovascular-disease patient advocacy organizations. The initiative supports stakeholder engagement and awareness but is unlikely to materially affect near-term revenue or valuation. Grant program announcement
- Neutral Sentiment: Management presented at the Morgan Stanley Global Healthcare Conference, giving investors an opportunity to assess the company’s pipeline and commercialization plans. No clearly identified new major catalyst was provided in the supplied coverage. Morgan Stanley conference transcript
- Negative Sentiment: Commentary titled “Why Myqorzo Doesn’t Make Me a Buyer Yet” reflects investor caution about Myqorzo’s ability to establish a sufficiently attractive commercial opportunity. That skepticism can pressure CYTK until prescriptions, adoption, and revenue traction provide stronger evidence of the drug’s potential. Myqorzo investment commentary
Wall Street Analyst Weigh In
Several brokerages have commented on CYTK. Mizuho boosted their target price on shares of Cytokinetics from $100.00 to $118.00 and gave the stock an "outperform" rating in a research report on Wednesday, June 24th. Royal Bank Of Canada reduced their price objective on shares of Cytokinetics from $117.00 to $112.00 and set an "outperform" rating for the company in a research note on Friday, August 7th. Barclays boosted their price objective on shares of Cytokinetics from $95.00 to $110.00 and gave the stock an "overweight" rating in a report on Thursday, August 13th. Wall Street Zen lowered shares of Cytokinetics from a "hold" rating to a "sell" rating in a research report on Saturday, August 29th. Finally, JPMorgan Chase & Co. increased their target price on shares of Cytokinetics from $97.00 to $103.00 and gave the company an "overweight" rating in a report on Thursday, August 13th. Eighteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Cytokinetics currently has a consensus rating of "Moderate Buy" and an average target price of $103.37.
Get Our Latest Stock Analysis on CYTK
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the company. Handelsbanken Fonder AB raised its position in shares of Cytokinetics by 63.8% during the 2nd quarter. Handelsbanken Fonder AB now owns 405,000 shares of the biopharmaceutical company's stock worth $34,502,000 after purchasing an additional 157,700 shares during the last quarter. Royce & Associates LP increased its position in Cytokinetics by 44.3% during the fourth quarter. Royce & Associates LP now owns 144,426 shares of the biopharmaceutical company's stock worth $9,177,000 after buying an additional 44,343 shares in the last quarter. Norges Bank acquired a new position in shares of Cytokinetics in the fourth quarter worth $51,281,000. Eventide Asset Management LLC lifted its position in shares of Cytokinetics by 181.9% in the fourth quarter. Eventide Asset Management LLC now owns 479,611 shares of the biopharmaceutical company's stock valued at $30,473,000 after acquiring an additional 309,503 shares in the last quarter. Finally, Siren L.L.C. purchased a new stake in shares of Cytokinetics in the first quarter valued at $40,466,000.
Cytokinetics Company Profile
(
Get Free Report)
Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. The company applies expertise in muscle physiology and contractility to develop potential treatments for cardiovascular and neuromuscular diseases.
Its leading programs include aficamten, an investigational cardiac myosin inhibitor being developed for conditions involving abnormal heart-muscle contraction, including hypertrophic cardiomyopathy.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
